Crossmark

MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway

Crossref DOI link: https://doi.org/10.1186/s12885-018-5218-4

Published Online: 2018-12-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Yue

Zhang, Shihong

Wang, Yuanjian

Peng, Jin

Fang, Fang

Yang, Xingsheng http://orcid.org/0000-0002-4946-2033
Funding

Funding for this research was provided by:

Foundation of National Nature Science in China (No.81372809)

National Clinical Research Center for Gynecological Oncology (No.2015BAI13B05)

the Department of Medical and Health Science Technology of Shandong Province (No.2016WS0345)
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 21 May 2018

Accepted: 13 December 2018

First Online: 29 December 2018

Ethics approval

: All experimental procedures were approved by the Laboratory Animal Ethics Committee of Qilu Hospital, Shandong University. The principles outlined in the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and Basel declaration (including the 3 R concept) were considered when planning experiments.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.